<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of resistant hypertension
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of resistant hypertension
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of resistant hypertension
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert D Brook, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raymond R Townsend, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William B White, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1238747643">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistant hypertension is defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses and at appropriate dosing frequency, one of which should be a diuretic (the diuretic should be selected based upon kidney function) [
         <a href="#rid1">
          1-5
         </a>
         ]. The diagnosis of true resistant hypertension requires that pseudoresistance, including white coat hypertension and nonadherence to treatments, has been excluded as a reason for the uncontrolled blood pressure  (
         <a class="graphic graphic_algorithm graphicRef127818" href="/z/d/graphic/127818.html" rel="external">
          algorithm 1
         </a>
         ). Patients with blood pressures at goal while taking four or more antihypertensive medications are considered to have "controlled resistant hypertension."
        </p>
        <p>
         Patients with resistant hypertension are at high risk for adverse cardiovascular events and are more likely to have a secondary cause of high blood pressure, which may be at least in part reversible. By definition they require more aggressive medication treatment, as well as the potential use of specialized interventions, to control their high blood pressure [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The treatment and prognosis of resistant hypertension that is not due to secondary causes will be reviewed here. The definition, epidemiology, risk factors, diagnosis, and evaluation of resistant hypertension, and secondary causes of hypertension, such as renovascular disease and primary aldosteronism, are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3862.html" rel="external">
          "Evaluation of secondary hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The treatment of resistant hypertension in patients receiving dialysis or who have a kidney allograft are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1848.html" rel="external">
          "Hypertension in patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1139604626">
         <span class="h1">
          TREATMENT GOAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal blood pressure for patients with resistant hypertension is the same as that in patients with hypertension without treatment resistance  (
         <a class="graphic graphic_table graphicRef117101" href="/z/d/graphic/117101.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]. Goal blood pressure is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H521206260">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2530829053">
         <span class="h2">
          Identify and treat secondary causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         An essential component of the management of resistant hypertension is identification and subsequent treatment of potentially reversible causes of secondary hypertension  (
         <a class="graphic graphic_table graphicRef77787" href="/z/d/graphic/77787.html" rel="external">
          table 2
         </a>
         ). While the actual prevalence of secondary causes in resistant hypertension is not well described, it is likely higher than in the general population of patients with hypertension [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         The most common secondary causes are obstructive sleep apnea (OSA), primary aldosteronism, and renal artery stenosis [
         <a href="#rid9">
          9
         </a>
         ]. The possible presence of secondary rather than primary hypertension (formerly called "essential" hypertension) is suggested by a number of clinical clues, one of which is resistant hypertension. Thus, secondary hypertension should be considered in most patients with resistant hypertension:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The evaluation for secondary hypertension in patients with resistant hypertension is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension", section on 'Secondary causes of hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension", section on 'Other components of evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical clues suggesting secondary hypertension are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3862.html" rel="external">
          "Evaluation of secondary hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of secondary hypertension frequently differs from the treatment of primary hypertension and depends upon the specific disorder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary aldosteronism (see
         <a class="medical medical_review" href="/z/d/html/141.html" rel="external">
          "Treatment of primary aldosteronism"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renovascular hypertension (see
         <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">
          "Treatment of unilateral atherosclerotic renal artery stenosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">
          "Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstructive sleep apnea (OSA) (see
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pheochromocytoma (see
         <a class="medical medical_review" href="/z/d/html/142.html" rel="external">
          "Treatment of pheochromocytoma in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cushing's syndrome (see
         <a class="medical medical_review" href="/z/d/html/174.html" rel="external">
          "Overview of the treatment of Cushing syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic coarctation (see
         <a class="medical medical_review" href="/z/d/html/5784.html" rel="external">
          "Management of coarctation of the aorta"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperparathyroidism or hypothyroidism (see
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3522186622">
         <span class="h2">
          Stop medications that raise blood pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of medications can raise the blood pressure and worsen underlying hypertension  (
         <a class="graphic graphic_table graphicRef56767" href="/z/d/graphic/56767.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid10">
          10,11
         </a>
         ]. Of these, nonsteroidal antiinflammatory drugs (NSAIDs) are probably the most common. (See
         <a class="medical medical_review" href="/z/d/html/2385.html" rel="external">
          "NSAIDs and acetaminophen: Effects on blood pressure and hypertension"
         </a>
         .)
        </p>
        <p>
         Patients with resistant hypertension who are taking a medicine that can exacerbate hypertension should discontinue the medication (or have the dose reduced), provided that doing so would not be harmful.
        </p>
        <p class="headingAnchor" id="H3987793197">
         <span class="h2">
          Prescribe lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifestyle modification (eg, weight loss, exercise, eating a healthy diet) has multiple health benefits and can also lower blood pressure  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Nonpharmacologic therapy'
         </a>
         .)
        </p>
        <p>
         Results from a few studies provide evidence for the safety and efficacy of exercise and lifestyle modifications specifically in patients with resistant hypertension [
         <a href="#rid12">
          12-14
         </a>
         ]. Moreover, several factors, in particular obesity and high sodium intake, are known to increase the risk for resistant hypertension [
         <a href="#rid1">
          1
         </a>
         ]. As such, nonpharmacologic therapies are recommended to help control blood pressure and reduce the need for further medications in such patients. The main modalities include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following the Dietary Approaches to Stop Hypertension (DASH) diet (see
         <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">
          "Diet in the treatment and prevention of hypertension"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reducing sodium intake and increasing potassium intake (see
         <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">
          "Salt intake and hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3876.html" rel="external">
          "Potassium and hypertension"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Losing weight (in obese and overweight patients) (see
         <a class="medical medical_review" href="/z/d/html/3875.html" rel="external">
          "Overweight, obesity, and weight reduction in hypertension"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exercising (see
         <a class="medical medical_review" href="/z/d/html/3828.html" rel="external">
          "Exercise in the treatment and prevention of hypertension"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderating alcohol intake (if excessive) (see
         <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">
          "Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Hypertension'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         It may be difficult for patients to achieve lasting lifestyle and dietary changes. Thus, professional guidance and follow-up with a certified dietitian or nutritionist should be provided, if available.
        </p>
        <p class="headingAnchor" id="H1758636568">
         <span class="h2">
          Address nonadherence to antihypertensive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonadherence to antihypertensive therapy is a major contributor to inadequate blood pressure control and is a common problem in patients who have apparent treatment resistance. As an example, in a systematic review of studies that performed objective assessments of drug adherence (ie, with urine or blood testing), approximately 40 percent of patients with apparent resistant hypertension were either partially or completely nonadherent to antihypertensive therapy [
         <a href="#rid15">
          15
         </a>
         ]. Another systematic review reached similar conclusions [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension", section on 'Apparent, true, and pseudoresistant hypertension'
         </a>
         .)
        </p>
        <p>
         Regimens should be simplified, and long-acting combination agents should be used as much as possible in order to reduce the number of prescribed pills and to permit once-daily dosing. Treatment adherence worsens as the use of pills, complexity of the dosing regimen, and out-of-pocket costs increase. Medication-related adverse effects should be discussed, and side effects should be addressed, with down-titration of or substitution for the offending agent. Patients who have real or perceived side effects to many different antihypertensive drugs are often the most difficult to treat [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The assessment of adherence to antihypertensive therapy and strategies to improve adherence are presented in detail elsewhere  (
         <a class="graphic graphic_table graphicRef77847" href="/z/d/graphic/77847.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3845.html" rel="external">
          "Patient adherence and the treatment of hypertension", section on 'Assessment of adherence'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3845.html" rel="external">
          "Patient adherence and the treatment of hypertension", section on 'Methods to improve adherence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H151107325">
         <span class="h2">
          Stepwise approach to pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following approach applies to patients with resistant hypertension who do not have a secondary cause of hypertension  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. Drug treatment may differ in patients with specific secondary causes. (See
         <a class="local">
          'Identify and treat secondary causes'
         </a>
         above.)
        </p>
        <p>
         By definition, patients with resistant hypertension are treated with at least three antihypertensive agents, including a diuretic (usually a thiazide, but loop diuretics are selected in patients with estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ). The specific regimen depends upon consideration of prior benefit, history of adverse events, financial limitations, and the presence of concomitant disease processes such as kidney disease and diabetes. Our general approach is to sequentially combine agents with different mechanisms of action. Specifically, the triple combination of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a long-acting dihydropyridine calcium channel blocker (usually
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         ), and a long-acting thiazide-like diuretic is often effective and generally well tolerated [
         <a href="#rid2">
          2,3
         </a>
         ]. In addition, in patients with uncontrolled blood pressure, medications should be provided at maximally tolerated doses and taken at the appropriate dosing frequency.
        </p>
        <p>
         However, most patients with resistant hypertension are being treated with an alternative three-drug regimen (other than the one described above). In addition, most who are prescribed four or more antihypertensive drugs are not receiving a mineralocorticoid receptor antagonist [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Our approach outlined here discusses the treatment of patients with confirmed resistant hypertension. Confirmation of treatment resistance is provided in a separate topic  (
         <a class="graphic graphic_algorithm graphicRef127818" href="/z/d/graphic/127818.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1302962219">
         <span class="h3">
          Switch to a more potent diuretic (if necessary)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients with resistant hypertension, our initial approach is to treat with more potent diuretic therapy  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are taking a thiazide-type diuretic (eg,
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ), and who have an eGFR ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we suggest switching to a thiazide-like diuretic (either
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ). In patients with an eGFR ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are already treated with a thiazide-like diuretic, and who have persistent signs of hypervolemia (ie, edema), we suggest adding a loop diuretic to the thiazide-like diuretic (ie, sequential nephron blockade).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally begin
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         at 12.5 mg daily, which requires splitting of the 25 mg pill, with subsequent titration up to 25 mg daily or, rarely, higher. If
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         is used, we start at 1.25 mg daily, titrating up to 5 mg daily as needed. For patients already being treated with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         , we discontinue it and substitute chlorthalidone or indapamide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we suggest using a thiazide-like diuretic (ie,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) or switching to a loop diuretic [
         <a href="#rid19">
          19,20
         </a>
         ]; if such patients are already taking a loop diuretic, then we intensify the loop diuretic dose, unless the patient develops signs of hypovolemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          Furosemide
         </a>
         and
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         are relatively short acting and usually require at least twice-daily dosing. A loop diuretic with a longer duration of action and more consistent absorption, such as
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         , may be more effective.
        </p>
        <p>
        </p>
        <p>
         Monitoring of serum electrolytes is necessary when diuretics are switched or when doses are changed. Hypokalemia is a more common problem in patients with resistant hypertension due at least in part to higher aldosterone levels, which explains the responsiveness of patients with resistant hypertension to mineralocorticoid receptor antagonists. (See
         <a class="local">
          'Add a mineralocorticoid receptor antagonist (if necessary)'
         </a>
         below.)
        </p>
        <p>
         Persistent volume expansion (whether or not it is sufficient to produce detectable peripheral edema) contributes to resistant hypertension, even among patients treated with conventional doses of thiazide-type diuretics. This was illustrated in a study of 279 patients with resistant hypertension, 85 percent of whom were being treated with a thiazide diuretic [
         <a href="#rid21">
          21
         </a>
         ]. Serum brain-type natriuretic peptide and atrial natriuretic peptide levels were significantly higher among patients with resistant hypertension compared with controls, suggesting hypervolemia.
        </p>
        <p>
         Effective diuretic use is almost always necessary to achieve blood pressure control in patients with resistant hypertension [
         <a href="#rid22">
          22
         </a>
         ]. Diuretics should be titrated until the blood pressure goal is attained, the maximum recommended dose of the medication has been reached, or the patient develops signs suggestive of hypovolemia (eg, fatigue, orthostatic hypotension, or decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the serum creatinine concentration). If overdiuresis is suspected, diuretic therapy should be reduced.
        </p>
        <p>
         In patients without severe kidney function impairment, the thiazide-like diuretics, including
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         , are preferred over
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         for the treatment of resistant hypertension [
         <a href="#rid23">
          23
         </a>
         ]. Chlorthalidone and indapamide have more potent antihypertensive effects than hydrochlorothiazide due, in part, to their longer half-lives. The supportive data are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
         Most studies that have compared
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         have evaluated patients with mild to moderate hypertension. Limited data suggest that chlorthalidone also provides comparatively greater benefit in patients with resistant hypertension [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Among patients with an eGFR of less than 30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , thiazide-type diuretics (such as
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ) are less effective. Thiazide-like diuretics (ie,
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         and
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) and loop diuretics, such as
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">
          torsemide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         , are often necessary for effective volume and blood pressure control [
         <a href="#rid19">
          19,25
         </a>
         ]. One option is to discontinue the thiazide-type diuretic and initiate chlorthalidone therapy; an alternative is to replace the thiazide-type diuretic with a loop diuretic. However, it is not uniformly necessary to discontinue the thiazide-type diuretic. Adding a loop diuretic in combination with a thiazide-type diuretic (termed sequential nephron blockade) can be highly effective in patients with resistant hypertension and chronic kidney disease [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3302092108">
         <span class="h3">
          Add a mineralocorticoid receptor antagonist (if necessary)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with resistant hypertension and uncontrolled blood pressure despite potent diuretic therapy, we suggest adding a mineralocorticoid receptor antagonist (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         or
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         )  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ). A potassium-sparing diuretic (eg,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         ,
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         ) is an alternative if a mineralocorticoid receptor antagonist cannot be used.
        </p>
        <p>
         We usually begin
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         at 12.5 mg once daily (which requires splitting of a 25 mg tablet) before titrating to 25 and, if necessary, 50 mg once daily. The risk of adverse effects such as gynecomastia, breast tenderness, and erectile dysfunction increases with higher doses. We generally do not increase the spironolactone dose above 50 mg once daily unless the patient has proven primary aldosteronism. The more specific aldosterone blocker,
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         , does not induce the side effects seen with spironolactone. However, eplerenone is less potent and often requires twice-daily dosing (ie, 50 mg twice daily) to be as effective for blood pressure lowering. An eplerenone dose of 50 mg once daily can be prescribed as initial trial, with escalation to 50 mg twice daily (or 100 mg once daily) as needed to achieve blood pressure control.
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          Amiloride
         </a>
         5 to 10 mg/day may also be an effective alternative to spironolactone.
        </p>
        <p>
         The serum potassium should be measured (usually in conjunction with measurement of other electrolytes and creatinine) two to four weeks after initiation or dose titration of a mineralocorticoid receptor antagonist. Measuring at two weeks, rather than waiting until four weeks, is appropriate in patients if one or more of the following factors is present: baseline serum potassium at the upper end of the normal range; use of an ACE inhibitor or ARB; or chronic kidney disease.
        </p>
        <p>
         Patients who are being treated with mineralocorticoid receptor antagonists or potassium-sparing diuretics are at risk for the development of hyperkalemia [
         <a href="#rid27">
          27
         </a>
         ]. The risk is increased among patients with chronic kidney disease and among those who are also treated with other drugs that can cause hyperkalemia, such as ACE inhibitors, ARBs, NSAIDs. (See
         <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">
          "Causes and evaluation of hyperkalemia in adults"
         </a>
         .)
        </p>
        <p>
         A variety of interventions can be used in patients with resistant hypertension who develop hyperkalemia but who require
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         for effective blood pressure control. Actions include lowering the dose of other offending medications (ACE inhibitors, ARBs), using loop diuretics, and prescribing gastrointestinal cation exchangers, which can permit patients with reduced kidney function to remain on mineralocorticoid receptor antagonists [
         <a href="#rid28">
          28
         </a>
         ]. The treatment and prevention of hyperkalemia in such patients is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults", section on 'Patients who can have the serum potassium lowered slowly'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         , and
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         provide significant antihypertensive benefit when added to existing multiple-drug regimens in patients with resistant hypertension [
         <a href="#rid29">
          29-35
         </a>
         ]. This effect may reflect, at least in part, significantly higher plasma aldosterone levels in patients with resistant hypertension compared with individuals who have normal blood pressure or controlled hypertension on one or two medications [
         <a href="#rid21">
          21
         </a>
         ]. However, spironolactone, which has been most widely studied, can also lower the blood pressure in patients with resistant hypertension who have normal plasma and urine aldosterone levels [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         The effect of
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         in patients with resistant hypertension has been evaluated in multiple randomized trials, each of which found that it was more effective than placebo or other antihypertensive drugs [
         <a href="#rid26">
          26,31,33,36-38
         </a>
         ]. The most compelling data come from the PATHWAY-2 trial, a randomized, double-blind crossover study comparing spironolactone (25 to 50 mg/day) with placebo,
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">
          bisoprolol
         </a>
         in 285 patients with resistant hypertension (mean clinic blood pressure 157/90 mmHg and mean home blood pressure 148/84 mmHg despite therapy with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic) [
         <a href="#rid36">
          36
         </a>
         ]. Spironolactone significantly reduced mean home systolic pressure at 12 weeks by nearly 9 mmHg compared with placebo and by between 4 to 5 mmHg compared with doxazosin and bisoprolol. The superiority of spironolactone did not depend upon the plasma renin activity. Hyperkalemia developed in 2 percent of patients taking spironolactone; the frequency of serious adverse events and withdrawal of therapy due to adverse events was similar with each antihypertensive drug.
        </p>
        <p>
         The antihypertensive effect of
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         was evaluated in a post-hoc observational analysis of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which included 1411 patients whose blood pressure was not controlled on three antihypertensive drugs (mean blood pressure 157/85 mmHg) [
         <a href="#rid30">
          30
         </a>
         ]. The mean baseline serum potassium was 4.2 mEq/L, and the mean serum creatinine was 1.1 mg/dL (99 micromol/L). The addition of spironolactone (median dose 25 mg/daily) as a fourth drug was associated with a mean 22/10 mmHg reduction in blood pressure at one-year follow-up. The mean rise in serum potassium was 0.4 mEq/L, with hyperkalemia (serum potassium &gt;5.5 mEq/L) occurring in 4 percent.
        </p>
        <p>
         In a substudy of the PATHWAY-2 trial described above,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         10 mg once daily was equally effective in lowering clinic blood pressure, compared with
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         25 mg once daily. These findings illustrate that amiloride may be an effective alternative as the fourth-line medication in resistant hypertension.
        </p>
        <p class="headingAnchor" id="H1175838555">
         <span class="h3">
          Additional drugs (if necessary)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients remain hypertensive despite taking a four-drug regimen that ideally includes a thiazide-like diuretic, such as
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         , and a mineralocorticoid receptor antagonist, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . There is little evidence to help guide the choice of a fifth antihypertensive medication in such patients.
        </p>
        <p>
         Patient factors (eg, preferences, side effects) and other characteristics can help guide choices  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ). As an example, those with faster heart rates (eg, &gt;70 beats per minute) may benefit from next adding a beta blocker. A vasodilating beta blocker, such as
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9461" href="/z/d/drug information/9461.html" rel="external">
          nebivolol
         </a>
         may provide more antihypertensive benefit with fewer side effects compared with traditional beta blockers, particularly when high doses are used (although head-to-head, full-dose comparisons are lacking) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Centrally acting agents that lower sympathetic activity may also be effective, and some data suggest that patients whose blood pressure remains uncontrolled on five or more medications have excess sympathetic nervous system activity [
         <a href="#rid40">
          40
         </a>
         ]. However, adverse effects are more common with these agents (eg, somnolence, dry mouth), and high-quality data to support their use are lacking. Potential choices include
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         (taken two to three times per day orally or applied as a dermal patch formulation changed weekly), clonidine extended release (taken once daily), or
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         (taken once daily, often at bedtime, when somnolence may be a small advantage).
        </p>
        <p>
         Other medication options include alpha-1 antagonists such as
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         or direct vasodilators (
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">
          minoxidil
         </a>
         ). The direct vasodilators hydralazine and minoxidil are generally reserved for patients who remain hypertensive despite trying the other approaches previously listed. Fluid retention and tachycardia are common side effects, and loop diuretics are often needed to control hypervolemia. Minoxidil also causes hirsutism, which may be a particular problem in women.
        </p>
        <p class="headingAnchor" id="H2079238895">
         <span class="h2">
          Multidisciplinary team approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is evidence that a team approach in the comprehensive care of hypertension patients can help improve the control of high blood pressure [
         <a href="#rid41">
          41-43
         </a>
         ]. This can potentially involve coordinated care and assistance from a variety of team members such as clinician specialists (eg, endocrinologists, nephrologists, cardiologists) along with nurses, physician assistants, pharmacists, community health workers, dieticians, social workers, and psychologists. There are few studies specifically in resistant hypertension; however, the evidence that a team approach is effective among patients with hypertension in general is growing. The merits of this strategy likely also apply to resistant hypertension, given the complex and often multifactorial etiology of inadequate blood pressure control in this population.
        </p>
        <p>
         In addition, involving patients in monitoring their own blood pressure at home may also improve control [
         <a href="#rid44">
          44
         </a>
         ]. Out-of-office monitoring can be especially effective to reduce blood pressure when undertaken in conjunction with other strategies to control hypertension (eg, telemedicine, multidisciplinary teams).
        </p>
        <p class="headingAnchor" id="H3362684735">
         <span class="h2">
          When to refer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to a hypertension specialist is appropriate for the following patients [
         <a href="#rid1">
          1,45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a specific secondary cause of hypertension is suspected
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the blood pressure remains elevated despite six months of intensive treatment with at least three drugs from those described above (see
         <a class="local">
          'Stepwise approach to pharmacologic therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         In the United States, the American Hypertension Specialist Certification Program provides a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ahscp.org%2F&amp;token=%2BCjrhIBVW0jZK35njTvgcaz4jBU4uoUDmG5GFSLNBw4%3D&amp;TOPIC_ID=3819" target="_blank">
          list of certified specialists
         </a>
         . The American Heart Association certifies and provides a list of accredited Comprehensive Hypertension Centers and Hypertension Practice Centers for referrals.
        </p>
        <p class="headingAnchor" id="H3705813189">
         <span class="h1">
          EXPERIMENTAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple experimental therapies have been evaluated for resistant hypertension including renal denervation techniques, novel medications [
         <a href="#rid46">
          46-51
         </a>
         ], and electrical stimulation of the carotid sinus baroreceptors.
        </p>
        <p class="headingAnchor" id="H2801029829">
         <span class="h2">
          Renal denervation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Denervation of the renal sympathetic nerves, either by catheter-based radiofrequency ablation or by catheter-based ultrasound ablation, reduces blood pressure in patients without resistant hypertension [
         <a href="#rid52">
          52-56
         </a>
         ] as well as in patients with resistant hypertension [
         <a href="#rid57">
          57-59
         </a>
         ].
        </p>
        <p>
         Four sham-controlled trials demonstrated modest short-term effects of renal nerve denervation on 24-hour ambulatory blood pressure in patients
         <strong>
          not
         </strong>
         taking antihypertensive medication (reductions of 4/3 mmHg, 4/2 mmHg, 5/4 mmHg, and 6/4 mmHg at two to three months, compared with a sham procedure) [
         <a href="#rid53">
          53-56
         </a>
         ]. The findings of another trial in patients with treated hypertension (but
         <strong>
          not
         </strong>
         resistant hypertension) showed a reduction in 24-hour ambulatory blood pressure of 7/4 mmHg at six months and 10/6 mmHg at 36 months, compared with sham denervation [
         <a href="#rid52">
          52,60
         </a>
         ].
        </p>
        <p>
         In patients with resistant hypertension, the best data come from a large, blinded, randomized trial (SYMPLICITY HTN-3) [
         <a href="#rid57">
          57,59,61
         </a>
         ]. In SYMPLICITY HTN-3, 535 patients with treatment-resistant hypertension (systolic pressure &gt;160 mmHg despite three or more antihypertensive medications, including a diuretic) were assigned to renal nerve denervation or a sham procedure; at six months, blood pressure decreased to a similar degree in both groups [
         <a href="#rid57">
          57
         </a>
         ]. However, renal denervation produced a larger decrease in ambulatory systolic blood pressure at 12 months (-7.5 versus -0.1 mmHg) and 36 months (-15.6 versus -0.3 mmHg) [
         <a href="#rid59">
          59
         </a>
         ]. There were no differences in the incidence of serious adverse events.
        </p>
        <p>
         In another sham-controlled trial (RADIANCE-HTN TRIO), 136 patients with resistant hypertension despite treatment with a three-drug single-pill combination (containing a dihydropyridine calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic) were randomly assigned to renal denervation or sham procedure [
         <a href="#rid62">
          62,63
         </a>
         ]. At two months, renal denervation produced a larger decrease in daytime ambulatory systolic pressure (-8 versus -3 mmHg). Thereafter, medication adjustment was permitted, and blood pressure declined more in the sham-controlled group; at six months, the daytime ambulatory systolic pressures were similar (138 mmHg in the denervation group and 139 mmHg in the sham group). Patients in the denervation group were prescribed slightly less antihypertensive medication at six months (3.8 versus 4.1 medications), but this difference was not statistically significant.
        </p>
        <p>
         Several unblinded studies provide conflicting data [
         <a href="#rid64">
          64-79
         </a>
         ]. As an example, an open-label randomized trial (Renal Denervation for Hypertension [DENERHTN]) compared stepped antihypertensive therapy alone with stepped antihypertensive therapy plus renal denervation in 106 patients with confirmed resistant hypertension despite therapy with
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         (or
         <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">
          irbesartan
         </a>
         if allergic to ACE inhibitors) [
         <a href="#rid64">
          64
         </a>
         ]. Stepped antihypertensive therapy consisted of
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">
          bisoprolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         , and rilmenidine added (in that order) at monthly intervals if home blood pressure remained above 135/85 mmHg. At six months, the change in 24-hour ambulatory systolic pressure decreased significantly more in the denervation group (-15.4 versus -9.5 mmHg). However, this study had several limitations. All patients lost to follow-up were in the denervation group and were not analyzed, the number of antihypertensive medications used at six months was similar in both groups, and the baseline blood pressure was higher in the denervation group, suggesting that the results could be due in part to regression to the mean.
        </p>
        <p>
         Conversely, in several other trials, there was no substantial benefit from renal denervation [
         <a href="#rid76">
          76-79
         </a>
         ]. As an example, the open-label SYMPATHY trial randomly assigned 139 patients with resistant hypertension to routine care or routine care plus renal nerve denervation [
         <a href="#rid76">
          76
         </a>
         ]. At six months, 24-hour ambulatory systolic pressure decreased more in the control group than in the denervation group (a decline of 6.6 versus 5.6 mmHg), although this was not statistically significant.
        </p>
        <p class="headingAnchor" id="H3353437653">
         <span class="h2">
          Novel medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various medications have been developed that may become useful in the management of patients with resistant hypertension [
         <a href="#rid46">
          46-51
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aldosterone synthase inhibitors – Lorundrostat, an aldosterone synthase inhibitor, was tested in a trial of 163 patients with uncontrolled hypertension despite antihypertensive drug therapy (58 percent taking two, and 42 percent taking three or more, antihypertensive medications); all patients had a suppressed plasma renin activity (≤1.0 ng/mL per hour) [
         <a href="#rid50">
          50
         </a>
         ]. Compared with placebo, lorundrostat reduced automated office systolic blood pressure at eight weeks by 1.5 to 9.6 mmHg, depending upon the dose. Hyperkalemia and severe hyperkalemia developed in 14 and 3 percent, respectively, of patients assigned to the two highest doses of lorundrostat. A separate aldosterone synthase inhibitor (baxdrostat) produced similar reductions in blood pressure [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interfering RNA – In a trial of 84 patients with elevated blood pressure on no antihypertensive medications, a single subcutaneous injection of zilebesiran, a long-acting interfering RNA that inhibits angiotensinogen production by the liver, reduced 24-hour systolic blood pressure at 12 weeks by 13 to 16 mmHg compared with placebo, depending upon the dose [
         <a href="#rid51">
          51
         </a>
         ]. Blood pressure reductions persisted at six months. There were no deaths and no episodes of hyperkalemia; serious adverse events occurred in two patients (one who received zilebesiran and one who received placebo). In a separate group of 28 patients, zilebesiran blunted both the increase in blood pressure induced by a high-salt diet and decrease in blood pressure induced by taking an angiotensin receptor blocker [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H71248815">
         <span class="h2">
          Stimulation of carotid sinus baroreceptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulation of the carotid sinus baroreflex system, or baroreflex activation therapy (BAT), may decrease blood pressure in patients with resistant hypertension. Feasibility studies have shown reductions in blood pressure after implantation of different devices designed to stimulate the carotid baroreflex system [
         <a href="#rid80">
          80-84
         </a>
         ]. As with renal denervation, BAT is not approved for treatment of hypertension in the United States [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         In the Rheos Pivotal Trial, 265 patients with resistant hypertension (defined as a mean office blood pressure, based upon five readings, greater than 160/80 mmHg and a mean 24-hour ambulatory systolic blood pressure greater than or equal to 135 mmHg despite at least three antihypertensive medications including a diuretic) underwent surgical implantation of a device designed to stimulate the carotid baroreceptors [
         <a href="#rid86">
          86
         </a>
         ]. One month after surgery, patients were randomly assigned to have BAT turned on immediately or to have BAT turned on six months later. The patients were followed for at least 12 months.
        </p>
        <p>
         The major findings from this trial were as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At six months, patients receiving BAT had a nonsignificantly larger decrease in systolic pressure (16 versus 9 mmHg) and a nonsignificantly greater likelihood of having a 10 mmHg or larger decrease in systolic pressure (54 versus 46 percent). In addition, patients receiving BAT were significantly more likely to achieve a goal systolic pressure of 140 mmHg or lower (42 versus 24 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At 12 months, the mean reduction in systolic pressure in the BAT group was 25 mmHg; more than 80 percent of these patients had at least a 10 mmHg decrease in systolic pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Within one month of surgery, 35 percent of patients had a serious procedure-related adverse event, including nerve injury. In most patients, procedure-related adverse events resolved spontaneously. Seven patients died (3 percent), but none of the deaths were attributable to the device.
        </p>
        <p>
        </p>
        <p>
         After the 12-month trial phase ended, open-label follow-up continued for an average of 28 months [
         <a href="#rid87">
          87
         </a>
         ]; the antihypertensive effects of the device persisted, and there were no device-associated deaths.
        </p>
        <p>
         Because the Rheos Pivotal Trial failed in two of its five primary endpoints, it was not approved by the US Food and Drug Administration (FDA) for the indication of resistant hypertension in the United States; this device was therefore discontinued. However, a second-generation device, the Barostim Neo, is under investigation in Europe.
        </p>
        <p>
         A second type of BAT device, which is inserted into the carotid sinus by endovascular deployment (rather than surgical implantation), lowered 24-hour ambulatory blood pressure at six months by 21/12 mmHg in 30 patients with apparent resistant hypertension [
         <a href="#rid84">
          84
         </a>
         ]. Serious adverse events occurred in four patients (13 percent).
        </p>
        <p class="headingAnchor" id="H2366162200">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with resistant hypertension are more likely to have target-organ damage and are at greater risk of stroke, myocardial infarction, heart failure, and/or chronic kidney disease compared with patients who have more easily controlled hypertension [
         <a href="#rid88">
          88-92
         </a>
         ]. The high cardiovascular risk is attributable in part to long-standing, poorly controlled hypertension [
         <a href="#rid93">
          93
         </a>
         ] and to the coexistence of other cardiovascular risk factors, including left ventricular hypertrophy, obesity, diabetes, hyperlipidemia, chronic kidney disease, and obstructive sleep apnea (OSA).
        </p>
        <p class="headingAnchor" id="H3018256776">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">
          "Society guideline links: Hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4416.html" rel="external">
          "Patient education: High blood pressure in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4424.html" rel="external">
          "Patient education: High blood pressure treatment in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4415.html" rel="external">
          "Patient education: High blood pressure, diet, and weight (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant hypertension is defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses, one of which should be a diuretic. The diagnosis of true resistant hypertension requires that pseudoresistance, including white coat hypertension and nonadherence, has been excluded as a reason for the uncontrolled blood pressure  (
         <a class="graphic graphic_algorithm graphicRef127818" href="/z/d/graphic/127818.html" rel="external">
          algorithm 1
         </a>
         ). Patients with blood pressures at goal while taking four or more antihypertensive medications are considered to have "controlled resistant hypertension." (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The goal blood pressure for patients with resistant hypertension (which varies among guidelines) is the same as that in patients with hypertension without treatment resistance  (
         <a class="graphic graphic_table graphicRef117101" href="/z/d/graphic/117101.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Treatment goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An essential component of the management of resistant hypertension is identification and subsequent treatment of potentially reversible causes of secondary hypertension  (
         <a class="graphic graphic_table graphicRef77787" href="/z/d/graphic/77787.html" rel="external">
          table 2
         </a>
         ). The most common of these are obstructive sleep apnea (OSA), primary aldosteronism, and renal artery stenosis. The possible presence of secondary rather than primary hypertension is suggested by a number of clinical clues, one of which is resistant hypertension. Thus, secondary hypertension should be considered in most patients with resistant hypertension. (See
         <a class="local">
          'Identify and treat secondary causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a variety of medications can raise the blood pressure and worsen underlying hypertension  (
         <a class="graphic graphic_table graphicRef56767" href="/z/d/graphic/56767.html" rel="external">
          table 3
         </a>
         ); such medications should be stopped, provided that doing so would not be harmful. (See
         <a class="local">
          'Stop medications that raise blood pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lifestyle modification (eg, weight loss, exercise, eating a healthy diet) can be effective in resistant hypertension to lower blood pressure and has multiple health benefits. As such, nonpharmacologic therapies are recommended to help control blood pressure and reduce the need for further medications in patients with resistant hypertension. (See
         <a class="local">
          'Prescribe lifestyle modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonadherence to antihypertensive therapy is a major contributor to inadequate blood pressure control and should be addressed. Regimens should be simplified, and long-acting combination agents should be used as much as possible in order to reduce the number of prescribed pills and to permit once-daily dosing. Medication-related adverse effects should be discussed, and side effects should be addressed, with down-titration of or substitution for the offending agent. (See
         <a class="local">
          'Address nonadherence to antihypertensive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following
         <strong>
          stepwise approach
         </strong>
         to pharmacologic therapy applies to patients with
         <strong>
          confirmed
         </strong>
         resistant hypertension who do not have a reversible secondary cause of hypertension (since drug treatment may differ in patients with specific secondary causes)  (
         <a class="graphic graphic_figure graphicRef128204" href="/z/d/graphic/128204.html" rel="external">
          figure 1
         </a>
         ) (see
         <a class="local">
          'Stepwise approach to pharmacologic therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients who are taking a thiazide-type diuretic (eg,
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         ), and who have an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we suggest switching to a thiazide-like diuretic (either
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         or
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In patients with an eGFR ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are already treated with a thiazide-type diuretic and who have persistent signs of hypervolemia (ie, edema), we suggest adding a loop diuretic to the thiazide-type diuretic (ie, sequential nephron blockade) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, in patients with an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we suggest switching to either chlorthalidone or a loop diuretic (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); if such patients are already taking a loop diuretic, then we intensify the loop diuretic dose, unless the patient develops signs of hypovolemia. (See
         <a class="local">
          'Switch to a more potent diuretic (if necessary)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with resistant hypertension and uncontrolled blood pressure despite potent diuretic therapy, we suggest adding a mineralocorticoid receptor antagonist (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         or
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). A potassium-sparing diuretic (eg,
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         ,
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         ) is an alternative if a mineralocorticoid receptor antagonist cannot be used. (See
         <a class="local">
          'Add a mineralocorticoid receptor antagonist (if necessary)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some patients remain hypertensive despite taking a four-drug regimen that ideally includes a thiazide-like diuretic, such as
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         , and a mineralocorticoid receptor antagonist, such as
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         . Patient factors (eg, preferences, side effects) and other characteristics can help guide choices. As an example, those with faster heart rates (eg, &gt;70 beats per minute) may benefit from next adding a beta blocker. Centrally acting agents that lower sympathetic activity may also be effective, but adverse effects are more common. Other options include alpha-1 antagonists such as
         <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">
          doxazosin
         </a>
         or direct vasodilators (
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">
          minoxidil
         </a>
         ). The direct vasodilators hydralazine and minoxidil are generally reserved for patients who remain hypertensive despite trying the other approaches previously listed. (See
         <a class="local">
          'Additional drugs (if necessary)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referral to a hypertension specialist is appropriate for the following patients: if a specific secondary cause of hypertension is suspected or if the blood pressure remains elevated despite six months of intensive treatment with at least three drugs from those described above. (See
         <a class="local">
          'When to refer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2902383906">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David A Calhoun, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension 2018; 72:e53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39:3021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braam B, Taler SJ, Rahman M, et al. Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol 2017; 12:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SM, Gurka MJ, Calhoun DA, et al. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med 2018; 131:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahapatra R, Kaliyappan A, Chinnakali P, et al. Prevalence and Risk Factors for Resistant Hypertension: Cross-Sectional Study From a Tertiary Care Referral Hospital in South India. Cureus 2021; 13:e18779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kvapil T, Vaclavik J, Benesova K, et al. Prevalence of secondary hypertension in patients with resistant arterial hypertension. J Hypertens 2021; 39:e357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014; 311:2216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassel LE, Odum LE. Our own worst enemy: pharmacologic mechanisms of hypertension. Adv Chronic Kidney Dis 2015; 22:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saco-Ledo G, Valenzuela PL, Ruilope LM, Lucia A. Physical Exercise in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2022; 9:893811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes S, Mesquita-Bastos J, Garcia C, et al. Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension: A Randomized Clinical Trial. JAMA Cardiol 2021; 6:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial. Circulation 2021; 144:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension 2016; 68:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourque G, Ilin JV, Ruzicka M, et al. Nonadherence Is Common in Patients With Apparent Resistant Hypertension: A Systematic Review and Meta-analysis. Am J Hypertens 2023; 36:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151:1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanselin MR, Saseen JJ, Allen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med 2021; 385:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014; 39:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006; 47:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005; 7:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Sinha AD, Tu W. Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease. Circulation 2022; 146:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30:1656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens 2018; 36:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28:2329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 2018; 71:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990; 48:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matanes F, Khan MB, Siddiqui M, et al. An Update on Refractory Hypertension. Curr Hypertens Rep 2022; 24:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potthoff SA, Vonend O. Multidisciplinary Approach in the Treatment of Resistant Hypertension. Curr Hypertens Rep 2017; 19:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and Control of Hypertension: JACC Health Promotion Series. J Am Coll Cardiol 2018; 72:1278.
          </a>
         </li>
         <li class="breakAll">
          Hypertension Control Change Package, Second Edition. Million Hearts. http://millionhearts.hhs.gov/tools-protocols/action-guides/htn-change-package/index.html (Accessed on June 08, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 2004; 329:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzam O, Kiuchi MG, Ho JK, et al. New Molecules for Treating Resistant Hypertension: a Clinical Perspective. Curr Hypertens Rep 2019; 21:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 2021; 42:3741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira JP, Fitchett D, Ofstad AP, et al. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. Am J Hypertens 2020; 33:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med 2023; 388:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laffin LJ, Rodman D, Luther JM, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA 2023; 330:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med 2023; 389:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391:2346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390:2160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Saxena M, Wang Y, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA 2023; 329:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmieder RE, Mahfoud F, Azizi M, et al. European Society of Hypertension position paper on renal denervation 2018. J Hypertens 2018; 36:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014; 370:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397:2476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Mahfoud F, Weber MA, et al. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. JAMA Cardiol 2022; 7:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams B. Resistant hypertension: an unmet treatment need. Lancet 2009; 374:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA 2020; 323:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol 2013; 62:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J 2013; 34:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jager RL, de Beus E, Beeftink MM, et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension 2017; 69:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015; 65:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens 2016; 34:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens 2016; 34:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006; 44:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alnima T, Scheffers I, De Leeuw PW, et al. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens 2012; 30:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiering W, Williams B, Van der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017; 390:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohmeier TE, Hall JE. Device-Based Neuromodulation for Resistant Hypertension Therapy. Circ Res 2019; 124:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaksson H, Ostergren J. Prognosis in therapy-resistant hypertension. J Intern Med 1994; 236:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsujimoto T, Kajio H. Intensive Blood Pressure Treatment for Resistant Hypertension. Hypertension 2019; 73:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168:2340.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3819 Version 73.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30354828" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30165516" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2018 ESC/ESH Guidelines for the management of arterial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27895136" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recognition and Management of Resistant Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32370572" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2020 International Society of Hypertension Global Hypertension Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30142317" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34796068" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prevalence and Risk Factors for Resistant Hypertension: Cross-Sectional Study From a Tertiary Care Referral Hospital in South India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prevalence of secondary hypertension in patients with resistant arterial hypertension
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24893089" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Resistant hypertension: a review of diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22195528" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Drug-induced hypertension: an unappreciated cause of secondary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908474" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Our own worst enemy: pharmacologic mechanisms of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35665271" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Physical Exercise in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34347008" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34565172" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296995" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36715101" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nonadherence Is Common in Patients With Apparent Resistant Hypertension: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1888244" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Resistant hypertension in a tertiary care clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22042809" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34739197" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24526255" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18541823" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12019280" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Resistant hypertension: comparing hemodynamic management to specialist care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16446394" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Chlorthalidone: has it always been the best thiazide-type diuretic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16088299" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36037270" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728905" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19738369" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31533906" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356711" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17309946" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of spironolactone on blood pressure in subjects with resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20651602" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20409927" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536989" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14573330" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of low-dose spironolactone in subjects with resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15480108" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414968" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24107738" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29463627" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2249378" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35384577" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : An Update on Refractory Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28185122" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Multidisciplinary Approach in the Treatment of Resistant Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30190007" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prevention and Control of Hypertension: JACC Health Promotion Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30190007" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prevention and Control of Hypertension: JACC Health Promotion Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15194600" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Blood pressure control by home monitoring: meta-analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24352797" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31506798" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : New Molecules for Treating Resistant Hypertension: a Clinical Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34392331" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32369546" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36342143" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37690061" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37467498" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29803589" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32234534" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29803590" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28859944" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36853250" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24678939" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A controlled trial of renal denervation for resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30015759" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : European Society of Hypertension position paper on renal denervation 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36130612" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35390320" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24678938" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Renal denervation for resistant hypertension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34010611" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36350593" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25631070" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21093036" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332353" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19710497" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Renal sympathetic-nerve ablation for uncontrolled hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19748666" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Resistant hypertension: an unmet treatment need.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31961420" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23644092" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23780578" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23782649" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21403086" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595301" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Renal denervation in moderate to severe CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23786861" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28264922" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25824248" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27228432" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27327441" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20883933" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17145423" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20101001" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728906" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28870716" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30920919" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Device-Based Neuromodulation for Resistant Hypertension Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21816315" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22341199" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16280275" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11677373" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989899" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prognosis in therapy-resistant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22379110" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Incidence and prognosis of resistant hypertension in hypertensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30580680" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Intensive Blood Pressure Treatment for Resistant Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029499" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
